CRSwNP中dupilumab给药间隔延长的五年真实世界结局
该单中心回顾性队列纳入224例接受dupilumab治疗最长4.5年(模型推算至5年)的成人CRSwNP患者。dupilumab在鼻息肉负担、嗅觉功能和生活质量方面带来显著改善,6个月内达峰并维持至5年;
要点
- dupilumab治疗CRSwNP的疗效在6个月内达峰并维持至5年。
- 16%患者出现副作用,最常见为肌肉骨骼症状。
核心结论
- 长期dupilumab治疗提供持久的疾病控制和良好的安全性。
- 个体化延长给药间隔可维持疗效并减轻治疗负担,支持其在优化CRSwNP长期管理中的潜在作用,尤其适用于有困扰性副作用的患者。
研究设计与样本
- 回顾性单中心队列研究,纳入224例成人CRSwNP患者,其中37%为非甾体抗炎药加重呼吸道疾病。
- 患者接受dupilumab治疗最长4.5年,结局模型推算至5年,采用混合效应模型分析纵向变化。
主要发现
- dupilumab使鼻息肉负担、嗅觉功能和生活质量显著改善,6个月内达峰,据纵向模型维持至5年。
- 总体16%患者出现副作用,最常见为肌肉骨骼症状,其次为皮肤反应和注射部位反应。
临床怎么用
- 对于达到稳定疾病控制的CRSwNP患者,可考虑个体化延长dupilumab给药间隔以减轻治疗负担。
- 对出现困扰性副作用(如肌肉骨骼症状、皮肤反应)的患者,延长给药间隔可能有助于减少不良事件。
局限性
- 回顾性单中心设计。
- 给药间隔延长为患者自愿选择,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a persistent, often Type 2-mediated inflammatory disease that markedly impairs quality of life. While dupilumab provides rapid improvement, there is limited evidence on long-term outcomes beyond 2 years, and the clinical impact of dosing-interval extension remains unclear. We therefore set out to evaluate long-term real-world outcomes of dupilumab therapy in CRSwNP and assess the effectiveness and safety of dosing-interval extension after achieving disease control. METHODS: This retrospective single-center cohort included 224 adults with CRSwNP (37% with nonsteroidal anti-inflammatory drug-exacerbated respiratory disease) treated with dupilumab for up to 4.5 years with outcomes modeled to 5 years. Longitudinal changes in polyp size, symptom burden, olfaction, asthma control, and Type 2 biomarkers were analyzed using mixed-effects models. Outcomes were then compared between patients who maintained standard 2-week dosing and those who voluntarily extended dosing intervals after achieving stable control. RESULTS: Dupilumab led to significant improvements in polyp burden, olfactory function, and quality of life peaking within 6 months, with sustained benefit through 5 years according to longitudinal modeling. Forty percent of patients extended dosing intervals without loss of efficacy and reported fewer treatment-related adverse events. Overall, 16% experienced side effects, most commonly musculoskeletal complaints, followed by skin reactions and injection site reactions. CONCLUSION: Long-term dupilumab therapy provided durable disease control and excellent safety. Personalized dosing-interval extension maintained efficacy and reduced treatment burden, supporting its potential role in optimizing long-term management of CRSwNP, especially in patients with troublesome side effects.
引用
- Campion NJ, Petsiou DP, Fally FC, et al. Dosing Interval Extension of Dupilumab in CRSwNP: Five-Year Real World Outcomes. Int Forum Allergy Rhinol. 2026. PMID: 41769954. doi:10.1002/alr.70125
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。